AzTrials
AzTrials

Nosocomial InfectionTOTEMNCT06482463

Diagnostic of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis

A study testing CSF sample in people with Nosocomial Infection, run by University Hospital, Toulouse at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The TOTEM study is a single-center study designed to evaluate the performance of the D-lactate assay in cerebrospinal fluid (CSF) for the diagnosis of ventriculostomy-related nosocomial meningitis. Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Nosocomial Infection
What is being tested?
CSF sample
Could I receive a placebo?
No, everyone receives an active treatment
How many people
185 participants
Where
1 siteFrance
Study dates
12 Feb 2025to Feb 2027
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Age ⩾ 18 years.
  • Patient with an external ventriculostomy implanted at the Toulouse University Hospital.
  • Patient suspected of nosocomial meningitis due to a febrile syndrome (in the absence of any other identified infectious site), headache, nausea, lethargy, change in neurological status, meningeal syndrome, epileptic event and cutaneous or subcutaneous inflammation at the ventriculostomy site of insertion.
  • Patient having expressed oral consent, after free and informed information.
  • Patient affiliated to a social security scheme.

Who cannot join

  • Diagnosis of community meningitis.
  • Proven or suspected meningitis and/or ventriculitis during the previous month.
  • Diagnosis of nosocomial meningitis made in another medical centre prior to admission.
  • Short bowel syndrome.
  • Acute mesenteric ischaemia.
  • End-stage renal failure (GFR < 15 ml/min/m2).
Show all 10Show fewer
  • Peritoneal dialysis.
  • Patient participating in another research protocol with an exclusion period still in progress.
  • Pregnant or breastfeeding woman.
  • Patient under guardianship or trusteeship, persons placed under the protection of justice

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

France1 site, 1 recruiting
  • Toulouse Hospital

    Toulouse

    Guillaume MARTIN-BLONDEL, 0561778490, martin-blondel.g@chu-toulouse.fr

    Recruiting

Other trials in France

About this study

Official title: Diagnostic Significance of D-lactate in Cerebrospinal Fluid Level in Patients With Suspected Ventriculostomy-related Meningitis : a Pilot Study

The TOTEM study is a single-center study designed to evaluate the performance of the D-lactate assay in cerebrospinal fluid (CSF) for the diagnosis of ventriculostomy-related nosocomial meningitis. The study will be conducted in the neurosurgical intensive care unit of the Toulouse University Hospital, in patients with a suspected diagnosis of ventriculostomy-related nosocomial meningitis.

Read the detailed description

For each study participant, an additional CSF sample will be taken from the ventriculostomy during the routine sampling performed for the diagnosis of nosocomial meningitis. This sample will be stored at -80°C. Assays of D-lactate, procalcitonin (PCT), and pro-inflammatory cytokines (IL-1, IL-6, IL-8, TNFa) will be performed serially on these CSF samples.

If the CSF sample taken at inclusion does not meet the criteria for nosocomial meningitis, a second sample will be taken 48 to 96 hours later to reassess the cellularity of the CSF. Finally, the end-of-participation visit takes place after 4 weeks. Two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.

Being tested
CSF sample
Keywords
External ventriculostomy, Nosocomial meningitis, Bacterial meningitis
Medical subject headings
Cross Infection, Meningitis, Bacterial

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • CSF sampleBiological

    an additional CSF sample of 1 ml is taken from the external ventriculostomy

Study groups in NCT06482463
Study groupRoleWhat they receive
Ventriculostomy-related nosocomial meningitisExperimentalFinally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.
Receives: Biological: CSF sample
Absence of nosocomial meningitisOtherFinally, two neurosurgical reanimators will retrospectively diagnose nosocomial meningitis, or the absence of meningitis, according to the information from the patient's medical records.
Receives: Biological: CSF sample

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Comparison of Sensitivity of CSF D-Lactate for Ventriculostomy-Related Nosocomial Meningitis

    Calculation of the sensitivity obtained for the determination of CSF D-lactate in patients with suspected ventriculostomy-related nosocomial meningitis. Thes parameter will be compared with those obtained for the usual biological markers.

    Measured: Day 0

  2. Comparison of Specificity of CSF D-Lactate for Ventriculostomy-Related Nosocomial Meningitis

    Calculation of the specificity obtained for the determination of CSF D-lactate in patients with suspected ventriculostomy-related nosocomial meningitis. Thes parameter will be compared with those obtained for the usual biological markers.

    Measured: Day 0

Secondary outcomes (10)
  1. sensitivity Parameter of Combined D-Lactate and Pro-Inflammatory Cytokines in CSF

    sensitivity parameter calculated for the combined assay of D-lactate and pro-inflammatory cytokines in CSF.

    Measured: Day 0

  2. specificity Parameter of Combined D-Lactate and Pro-Inflammatory Cytokines in CSF

    specificity parameter calculated for the combined assay of D-lactate and pro-inflammatory cytokines in CSF.

    Measured: Day 0

  3. Sensitivity Parameter of Combined D-Lactate and and cyto-biochemical parameters in CSF.

    sensitivity parameter calculated for the combined assay of D-lactate and routinely assayed cyto-biochemical parameters (L-lactate, proteins, glucose, cellularity) in CSF.

    Measured: Day 0

  4. specificity Parameter of D-lactate and cyto-biochemical parameters in CSF.

    specificity parameter calculated for the combined assay of D-lactate and routinely assayed cyto-biochemical parameters (L-lactate, proteins, glucose, cellularity) in CSF.

    Measured: Day 0

  5. Sensitivity Parameter of D-lactate in CSF depending on the nature of the bacterial species identified.

    Sensitivity Parameter calculated for the D-lactate assay in CSF according to the nature of the bacterial species identified.

    Measured: Day 0

  6. specificity Parameter of D-lactate in CSF depending on the nature of the bacterial species identified.

    specificity Parameter calculated for the D-lactate assay in CSF according to the nature of the bacterial species identified.

    Measured: Day 0

  7. Sensitivity Parameter of D-lactate in CSF according to the presence or absence of antibiotic therapy before collection.

    Sensitivity Parameter calculated for the determination of D-lactate in CSF according to the presence or absence of antibiotic therapy prior to sampling.

    Measured: Day 0

  8. specificity Parameter of D-lactate in CSF according to the presence or absence of antibiotic therapy before collection.

    specificity Parameter calculated for the determination of D-lactate in CSF according to the presence or absence of antibiotic therapy prior to sampling.

    Measured: Day 0

  9. Sensitivity Parameter for the determination of CSF D-lactate in culture-negative bacterial meningitis.

    Densitivity Parameter calculated for the determination of D-lactate in CSF in culture-negative bacterial meningitis.

    Measured: Day 0

  10. specificity Parameter for the determination of CSF D-lactate in culture-negative bacterial meningitis.

    specificity Parameter calculated for the determination of D-lactate in CSF in culture-negative bacterial meningitis.

    Measured: Day 0

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Jul 2024
  2. Study start12 Feb 2025
  3. Primary completionFeb 2027 (estimated)
  4. Study completionFeb 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
185 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06482463
Sponsor's protocol ID
RC31/23/0614
Acronym
TOTEM
Status last verified
Dec 2025
First submitted
25 Jun 2024
Last updated
31 Dec 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing CSF sample in people with Nosocomial Infection, run by University Hospital, Toulouse at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 31 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Lucie LELIEVRE, Md (0561777198 ext. +33, lelievre.l@chu-toulouse.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Comparison of Sensitivity of CSF D-Lactate for Ventriculostomy-Related Nosocomial Meningitis (time frame: Day 0). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 31 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in